Sagimet Biosciences (SGMT) News Today $9.83 +1.47 (+17.58%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.99 +0.16 (+1.68%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Sagimet Biosciences Inc. (SGMT) - Yahoo FinanceJune 24 at 6:47 PM | finance.yahoo.comSagimet Biosciences Inc.June 14, 2025 | wsj.comTwo Sigma Investments LP Trims Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)Two Sigma Investments LP cut its stake in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 72.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 50,433 shares of the company's stock after selling 133,205 shares duringJune 12, 2025 | marketbeat.comSagimet Biosciences updates executive compensationJune 12, 2025 | investing.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...June 11, 2025 | morningstar.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025June 9, 2025 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Recommendation of "Moderate Buy" from BrokeragesSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recoJune 6, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Price Target Raised to $27.00 at Jones TradingJones Trading lifted their price target on shares of Sagimet Biosciences from $15.00 to $27.00 and gave the company a "buy" rating in a research note on Friday.June 6, 2025 | marketbeat.comSagimet Biosciences Analyst RatingsJune 5, 2025 | benzinga.comSagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne TreatmentJune 4, 2025 | marketwatch.comSagimet Biosciences shares soar on positive acne treatment trial resultsJune 4, 2025 | ca.investing.comSagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug ResultsJune 4, 2025 | msn.comSagimet climbs as acne therapy hits main goals in late-stage trial in ChinaJune 4, 2025 | msn.comSagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567June 4, 2025 | seekingalpha.comSagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner AscletisJune 4, 2025 | globenewswire.comMillennium Management LLC Buys 499,094 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT)Millennium Management LLC grew its stake in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 257.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 693,247 shares of the company's stock after purchasinJune 1, 2025 | marketbeat.comSagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatmentMay 24, 2025 | investing.comSagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction ...May 24, 2025 | morningstar.comSagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025May 22, 2025 | globenewswire.comSagimet Biosciences (SGMT) Expected to Announce Earnings on WednesdaySagimet Biosciences (NASDAQ:SGMT) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-sagimet-biosciences-inc-series-a-stock/)May 16, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Purchased by Bridgeway Capital Management LLCBridgeway Capital Management LLC raised its position in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 62.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 224,100 shares of the company's stock after purchasing anMay 13, 2025 | marketbeat.comRenaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT)Renaissance Technologies LLC lowered its stake in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 95.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,80May 10, 2025 | marketbeat.comSagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 9, 2025 | finanznachrichten.deSagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Alyeska Investment Group L.P.Alyeska Investment Group L.P. cut its holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 6.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,290,512 sharesMay 8, 2025 | marketbeat.comBoothbay Fund Management LLC Has $56,000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)Boothbay Fund Management LLC reduced its position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 89.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,518 shMay 7, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Baker BROS. Advisors LPBaker BROS. Advisors LP cut its holdings in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 31.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 952,996 shares of the company's stock after selling 428,90May 6, 2025 | marketbeat.com138,263 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by 683 Capital Management LLC683 Capital Management LLC purchased a new position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 138,263 shares of the companyMay 4, 2025 | marketbeat.comBlue Owl Capital Holdings LP Has $5.96 Million Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT)Blue Owl Capital Holdings LP lowered its position in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 20.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,323,877 shares of the company's stock after selling 35April 26, 2025 | marketbeat.comSagimet Biosciences announces presentations at EASL Congress 2025April 25, 2025 | markets.businessinsider.comSagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025April 23, 2025 | finance.yahoo.comSagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Down 15.9% in MarchSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 4,190,000 shares, a drop of 15.9% from the February 28th total of 4,980,000 shares. Approximately 18.0% of the shares of the company are sold short. Based on an average daily volume of 820,300 shares, the short-interest ratio is presently 5.1 days.April 2, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from AnalystsSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating toMarch 17, 2025 | marketbeat.comSagimet Biosciences (SGMT) Expected to Announce Earnings on MondaySagimet Biosciences (NASDAQ:SGMT) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports.March 17, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for SGMT EarningsSagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Sagimet Biosciences in a research note issued on Thursday, March 13th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($1.00) per sMarch 17, 2025 | marketbeat.comSagimet Biosciences Gets Clearance To Initiate Phase 1 Study Of TVB-3567 For Treatment Of AcneMarch 13, 2025 | nasdaq.comSagimet Biosciences (NASDAQ:SGMT) Announces Earnings Results, Beats Expectations By $0.15 EPSSagimet Biosciences (NASDAQ:SGMT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.15.March 13, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research note on Tuesday.March 12, 2025 | marketbeat.comSagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 12, 2025 | finanznachrichten.deSagimet Biosciences reports Q4 EPS (50c), consensus (63c)March 12, 2025 | markets.businessinsider.comSagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate UpdatesMarch 12, 2025 | globenewswire.comSagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567March 11, 2025 | markets.businessinsider.comSagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 11, 2025 | globenewswire.comSagimet Biosciences' Denifanstat Should Be Worth More TodayMarch 7, 2025 | seekingalpha.comIs Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?February 25, 2025 | msn.comIs Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?February 25, 2025 | msn.com10 Hot Penny Stocks to Buy NowFebruary 24, 2025 | insidermonkey.comSagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy NowFebruary 22, 2025 | insidermonkey.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from AnalystsSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buyFebruary 21, 2025 | marketbeat.comSagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone SymposiumFebruary 19, 2025 | markets.businessinsider.com Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMT Media Mentions By Week SGMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMT News Sentiment▼0.000.62▲Average Medical News Sentiment SGMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMT Articles This Week▼12▲SGMT Articles Average Week Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nurix Therapeutics News Today Praxis Precision Medicines News Today Pharvaris News Today Zymeworks News Today Mineralys Therapeutics News Today Ardelyx News Today ArriVent BioPharma News Today Syndax Pharmaceuticals News Today Cogent Biosciences News Today Oculis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMT) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
